ENGN

enGene Therapeutics Inc.

enGene Therapeutics Inc. (ENGN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA 0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -1.8%
Price Return 12M -72.4%
Catalyst Signal 0.00
Market Cap $111.9M
TTM Revenue N/A
Price / Sales N/A
ROE -60.5%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) C- (2.1) C+ (2.8) B- (2.9) C+ (2.6) C+ (2.8)
2026-11-04 B+ (3.7) C- (2.1) C+ (2.8) D+ (1.7) C+ (2.7) C+ (2.6)
2026-10-28 B+ (3.6) C- (2.1) B- (2.9) D+ (1.5) C+ (2.7) C+ (2.5)
2026-10-21 B+ (3.6) C- (2.0) B- (2.9) D+ (1.6) C+ (2.6) C+ (2.6)
2026-10-14 B+ (3.7) C- (2.1) B- (2.9) D+ (1.6) C+ (2.6) C+ (2.6)
Page 1 of 4